Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 943-950

  Schiffman, K S ^a,b,c   Bensinger, W I ^a,b,c   Appelbaum, F R ^a,b,c   Rowley, S ^a,b,c   Lilleby, K ^a,b,c   Clift, R A ^a,b,c   Weaver, C H ^a,b,c   Demirer, T ^a,b,c   Sanders, J E ^a,b,c   Petersdorf, S ^a,b,c   Gooley, T ^a,b,c   Weiden, P ^d   Zuckerman, N ^e   Montgomery, P ^e   Maziarz, R ^f   Klarnet, J P ^g   Rivkin, S ^a   Trueblood, K ^e   Storb, R ^a,b,c   Holmberg, L ^a,b,c   Buckner, C D ^a,b,c   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e St Luke's Mountain States Tumor Institute   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g St Joseph Hospital Tacoma   (United States)

Author keywords

Peripheral blood stem cells

Indexed keywords

BUSULFAN; CIPROFLOXACIN; DEXAMETHASONE; INTERLEUKIN 2; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER DISEASE; BREAST CANCER; CANCER; CANCER CENTER; CANCER REGRESSION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 8944252798     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
2. Lazarus HM, Reed MD, Spitzer TR et al. High-dose iv thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689-695.
3. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
4. Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1: 359-367.
5. Corringham R, Gilmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983; 52: 1783-1787.
6. Klumpp TR, Mangan KF, Glenn LD, Macdonald JS. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337-339.
7. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant (in press).
8. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-3163.
9. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
10. Cunningham D, Powles R, Malpas JS et al. A randomised trial of maintenance therapy with intron-a following high dose melphalan and ABMT in myeloma. ASCO 1993; 12: 1232(S) (Abstr.).
11. Fefer A, Benyunes M, Higuchi C et al. Interleukin-2+/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 1993; 89: 2-7.
12. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
13. Shuhart MC, McDonald GB, Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 454-481.
14. Crawford SW. Critical care and respiratory failure. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 513-526.
15. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
16. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983; 78: 427-434.
17. Fisher LD, Van Belle G. Biostatistics: A Methodology for the Health Sciences. John Wiley and Sons: New York, 1993.
18. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11: 1329-1335.
19. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
20. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
21. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
22. Meropol NJ, Overmoyer BA, Stadtmauer EA. High-dose chemotherapy with autologous stem cell support for breast cancer. Oncology 1992; 6: 53-69.
23. Weaver CH, Birch R, Schwartzberg LS, West WH. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift RA (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic: Norwell, 1995, (in press).
24. Van der Jagt RHC, Appelbaum FR, Petersen FB et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211-215.
25. Peters WP, Ross M, Vredenburgh JJ et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25-31.